CorVel (NASDAQ:CRVL – Get Free Report) released its quarterly earnings results on Tuesday. The business services provider reported $0.61 earnings per share (EPS) for the quarter, FiscalAI reports. CorVel had a return on equity of 30.15% and a net margin of 11.23%.The firm had revenue of $248.55 million for the quarter.
CorVel Stock Performance
NASDAQ:CRVL opened at $64.26 on Thursday. The stock’s 50-day simple moving average is $55.50 and its 200 day simple moving average is $61.82. The company has a market cap of $3.29 billion, a P/E ratio of 31.50 and a beta of 0.98. CorVel has a 52-week low of $44.83 and a 52-week high of $117.22.
Insider Activity
In related news, insider Maxim Shishin sold 2,400 shares of CorVel stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $54.00, for a total value of $129,600.00. Following the sale, the insider owned 7,050 shares of the company’s stock, valued at approximately $380,700. The trade was a 25.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 44.56% of the company’s stock.
Institutional Trading of CorVel
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings downgraded CorVel from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, April 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.
Read Our Latest Research Report on CRVL
About CorVel
CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.
The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).
See Also
- Five stocks we like better than CorVel
- Freight Boom: The Hormuz Blockade Payday
- The Palantir Paradox—Record Numbers and a Stock That Won’t Cooperate
- TJX Companies Fires on All Cylinders With 9% Revenue Growth
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
Receive News & Ratings for CorVel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorVel and related companies with MarketBeat.com's FREE daily email newsletter.
